PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Publication Type:

Journal Article


Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 17, Issue 8, p.2400-9 (2011)


2011, Adult, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Center-Authored Paper, Chemotherapy, Adjuvant, Clinical Research Division, Doxorubicin, Female, Fluorodeoxyglucose F18, Humans, Kinetics, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Outcome Assessment (Health Care), Positron-Emission Tomography, Prognosis, Proportional Hazards Models, Radiopharmaceuticals, Reproducibility of Results, Research Trials Office Core Facility - Biostatistics Service, Sensitivity and Specificity, Shared Resources, Survival Analysis


Changes in tumor metabolism from positron emission tomography (PET) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are predictive of pathologic response. Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS).